You just read:

Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" IND application for Phase 2 clinical study in the United States Indication for Corneal Endothelial Diseases [Developmental code: K-321]

News provided by

Kowa Company Ltd.

Sep 03, 2019, 10:00 ET